Evidence map›Paper›PMID 40330782›Full record

ArticleFrontiers in medicine2025

A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.

Lucia Masarova, Brandi N Reeves, Firas El Chaer, Lynda Foltz, Tsewang Tashi, Ghaith Abu-Zeinah, Jennifer Lucas, Anna B Halpern, Dawn Maze, Albert Qin and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Lucia MasarovaDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Brandi N ReevesDivision of Hematology, Department of Medicine, Blood Research Center, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Firas El ChaerDivision of Hematology and Oncology, Department of Medicine, The University of Virginia, Charlottesville, VA, United States.
Lynda FoltzDivision of Hematology, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
Tsewang TashiHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Ghaith Abu-ZeinahDivision of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States.
Jennifer LucasMedical Oncology and Hematology, Marin Cancer Care, Greenbrae, CA, United States.
Anna B HalpernUniversity of Washington Medical Center, Seattle, WA, United States.
Dawn MazePrincess Margaret Cancer Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Albert QinPharmaEssentia Corporation, Taipei, Taiwan.
Hana SafahOur Lady of the Lake Medical Center, Baton Rouge, LA, United States.
Fengshuo LanStony Brook University Medical Center, Stony Brook, NY, United States.
Casey L O'ConnellKeck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Swati GoelDepartment of Hematology and Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY, United States.
Lindsay ReinDepartment of Medicine, Duke University School of Medicine, Durham, NC, United States.
Bruno FangAstera Cancer Care, East Brunswick, NJ, United States.
Joan HowDana Farber Cancer Institute/Massachusetts General Hospital, Boston, MA, United States.
Sunil BabuFort Wayne Medical Oncology & Hematology, Fort Wayne, IN, United States.
Zhuoyan LiGreater Baltimore Medical Center, Baltimore, MD, United States.
Sonia CerquozziDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada.
Stephen T OhDivision of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.
Anthony M HunterDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States.
Nikolai PodoltsevHematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.
Pankit VachhaniO'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, AL, United States.
Abdulraheem YacoubHematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas, MO, United States.
Julia M CunninghamDivision of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, United States.
Christopher HillisDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Salman OtoukeshDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States.
Oleh ZagrijtschukPharmaEssentia USA, Burlington, MA, United States.
Henry CastroEverest Clinical Research, Markham, ON, Canada.
Prithviraj BoseDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical trialcomplete hematologic responseessential thrombocythemia (ET)higher initial dose and accelerated titration (HDAC) regimenmolecular responseropeginterferon alfa-2b-njft (ropeg)

Identifiers

PMID40330782
PMCPMC12054645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.